Engineered Tetanus Toxin Variants for Stable Vaccine Potency
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing vaccines for botulism and tetanus, such as chemically inactivated BoNT toxoid vaccines, suffer from declining potency, low antigenicity, and immunopotency, necessitating the development of non-catalytic, non-toxic variants of tetanus and botulinum toxins for use as adjuvants and conjugate vaccines.
Innovation Solution
Genetically engineered recombinant toxins with multiple mutations, such as R372A, Y375F, E234Q, R1226L, and W1289A, are developed to eliminate catalytic activity, receptor binding, and translocation potential, rendering them non-toxic and suitable for use as vaccines and conjugate vaccines.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemically inactivated BoNT toxoid vaccine is used, then vaccine protection is achieved, but potency declines over time
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of the toxin through genetic engineering. Specific amino acid mutations (e.g., E234Q, R372A, Y375F, K768A, R1226L, W1289A) are introduced to alter the toxin's catalytic and binding properties, creating a non-toxic variant that maintains immunogenicity without the potency decline associated with chemical inactivation.
Solution Approach 2:
The patent creates a functional copy of the native toxin that lacks harmful properties. By copying the toxin's protein structure and immunogenic epitopes while introducing specific mutations to eliminate catalytic activity and receptor binding, the invention produces a vaccine candidate that replicates the protective immune response without the toxicity and potency loss of conventional toxoids.
2Reliability
If conventional tetanus toxin fragment vaccines are used, then vaccination is achieved, but antigenicity and immunopotency are low
Solution Approach 1:
The patent segments the toxin into functional domains (heavy chain and light chain) and introduces mutations in specific segments to achieve the desired properties. By targeting specific regions (e.g., mutations in the heavy chain at positions R372, Y375, and light chain at positions E234, K768, R1226, W1289), the invention maintains the immunogenic segments while eliminating toxic functions.
Solution Approach 2:
The patent applies local quality by making specific regions of the toxin have different properties. Certain amino acid positions are mutated to eliminate toxicity (non-catalytic, non-receptor binding), while other regions are preserved to maintain antigenicity and immunopotency, creating a localized differentiation of functional properties within the protein structure.
3Object-affected harmful factors
If genetically engineered non-catalytic variants are used, then toxicity is reduced, but manufacturing complexity increases
Solution Approach 1:
The patent applies preliminary action by performing genetic engineering and mutation introduction during the protein production phase, before the toxin is used as a vaccine. The mutated gene is constructed in advance and expressed in host cells to produce the non-toxic variant, eliminating the need for complex post-production chemical modification steps.
4Object-affected harmful factors
If chemical cross-linking is used to reduce toxicity, then safety is improved, but vaccine formulation complexity increases
Solution Approach 1:
The patent replaces the chemical cross-linking mechanism with a genetic engineering approach. Instead of using chemical agents to inactivate the toxin and reduce toxicity, the invention uses specific amino acid mutations to inherently eliminate toxic properties, substituting a chemical process with a biological/genetic solution that simplifies formulation.
Data Source
AI summary
Provided herein are engineered non-catalytic, non-toxic tetanus toxin variants and methods of using such engineered tetanus toxin variants as low dose, protective vaccines that are non-toxic and more potent than their respective chemically inactivated toxoids. In addition, provided herein are conjugate vaccine carriers comprising engineered tetanus toxin variants and methods of using such conjugate vaccines to elicit T-cell dependent immune memory responses which can target a broad spectrum of microbial pathogens as a single vaccine.